Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Proper Citation: Ablynx (RRID:SCR_002940)
Description: A biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases including inflammation, hematology, oncology and pulmonary disease.
Abbreviations: Ablynx
Resource Type: production service resource, material service resource, reagent manufacture, service resource
Keywords: nanobody, protein, antibody fragment, human disease, oncology, hematology, tumor, blood, therapy, therapeutic, pharmaceutical, drug product, drug
Expand AllWe found {{ ctrl2.mentions.all_count }} mentions in open access literature.
We have not found any literature mentions for this resource.
We are searching literature mentions for this resource.
Most recent articles:
{{ mention._source.dc.creators[0].familyName }} {{ mention._source.dc.creators[0].initials }}, et al. ({{ mention._source.dc.publicationYear }}) {{ mention._source.dc.title }} {{ mention._source.dc.publishers[0].name }}, {{ mention._source.dc.publishers[0].volume }}({{ mention._source.dc.publishers[0].issue }}), {{ mention._source.dc.publishers[0].pagination }}. (PMID:{{ mention._id.replace('PMID:', '') }})
A list of researchers who have used the resource and an author search tool
A list of researchers who have used the resource and an author search tool. This is available for resources that have literature mentions.
No rating or validation information has been found for Ablynx.
No alerts have been found for Ablynx.
Source: SciCrunch Registry